8-K: ProKidney Secures Up to $200 Million in New At-the-Market Equity Offering

ProKidney Corp. has entered into a new Open Market Sale Agreement with Jefferies LLC, enabling the company to sell up to $200 million of its Class A common stock through an at-the-market offering.

Summary

• ProKidney Corp. (the "Company") signed an Open Market Sale Agreement (the "Sales Agreement") with Jefferies LLC (the "Sales Agent") on July 14, 2025.
• The Sales Agreement allows the Company to offer and sell shares of its Class A common stock, par value $0.0001 per share, with an aggregate offering price of up to $200,000,000.
• Sales of shares may occur through various methods, including ordinary broker transactions, to or through a market maker, on The Nasdaq Capital Market, in the over-the-counter market, or in privately negotiated transactions.
• Jefferies LLC will receive compensation of up to 3.0% of the gross offering proceeds from all shares sold through it.
• The Company is not obligated to sell any shares under the agreement and can suspend the offering at any time.
• This new Sales Agreement replaces and mutually terminates a previous Open Market Sale Agreement dated January 19, 2024, with the same Sales Agent.
• The sales will be made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-275701), which was initially filed on November 22, 2023, and declared effective on November 30, 2023, and further amended and declared effective on July 7, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it introduces potential dilution, it primarily signifies enhanced financial flexibility and access to capital for future operations and strategic initiatives, which is crucial for a development-stage company. The termination of the old agreement and entry into a new one is a routine update.

Positives

• Provides ProKidney Corp. with flexible access to capital, allowing the company to raise funds as needed without a single large offering.
• The at-the-market (ATM) structure offers efficiency and potentially lower costs compared to traditional underwritten offerings.
• The ability to suspend the offering at any time provides management with control over the timing and amount of capital raised, adapting to market conditions.

Negatives

• The offering introduces potential dilution for existing shareholders as new shares are sold into the market.
• The Sales Agent's compensation of up to 3.0% of gross proceeds represents a cost to the Company for raising capital.
• The actual amount and timing of funds raised are uncertain, as the Company has no obligation to sell shares and sales depend on market conditions.

Risks

• Potential dilution of existing shareholders' equity and voting power due to the issuance of new common stock.
• Market conditions may not be favorable for selling shares, limiting the Company's ability to raise the full $200 million or achieve desired pricing.
• The at-the-market nature of the offering could put downward pressure on the stock price if a significant volume of shares is sold over a short period.
• The Company's stock price must remain above a Floor Price of $1.00 per share, unless the Agent provides prior written consent, which could limit sales if the stock price falls.

Future Outlook

The new Open Market Sale Agreement provides ProKidney Corp. with a flexible mechanism to raise up to $200 million in capital, which can be utilized to support ongoing operations, research and development, or other strategic initiatives as needed, without committing to a fixed amount or timeline.

Management Comments

• The Sales Agreement was duly authorized, executed, and delivered by the Company.
• The Company has no obligation to sell any shares under the Sales Agreement and may at any time and from time to time suspend the offering of the shares.

Industry Context

At-the-market (ATM) equity offerings are a common financing tool, particularly for biotechnology and pharmaceutical companies like ProKidney, which often require significant capital for research, clinical trials, and commercialization efforts. This mechanism allows companies to access capital incrementally, reducing the immediate dilutive impact of a large single offering and providing flexibility to raise funds based on ongoing needs and market conditions.

Comparison to Industry Standards

• The structure of this ATM offering, including the sales agent compensation of up to 3.0% and the use of a shelf registration statement, is consistent with standard practices for public companies, particularly those in the biotech sector, seeking flexible capital access.
• The termination of a prior ATM agreement and entry into a new one is also a common procedural update, often done to refresh terms or offering amounts under an updated shelf registration.

Related Party Transactions

• Jefferies LLC, the Sales Agent, has provided and may continue to provide various financial advisory and investment banking services to the Company in the ordinary course of business, for which they receive customary fees and expense reimbursements.

Stakeholder Impact

• Shareholders: Potential for dilution as new shares are issued, which could impact per-share metrics and stock price. However, access to capital can support long-term growth and value creation.
• Company: Gains significant financial flexibility to fund operations, research, and development without the immediate pressure of a large, single capital raise.
• Creditors: Improved liquidity and financial stability from potential capital raises could indirectly benefit creditors by strengthening the Company's financial position.

Next Steps

• The Company may, at its discretion, sell shares of its Class A common stock from time to time under the new Sales Agreement.
• The Company will file prospectus supplements in connection with any sales of common stock under the at-the-market program.
• The Company will continue to comply with SEC reporting requirements, including filing quarterly and annual reports, and providing updates on sales under the agreement.

Key Dates

Keywords

ProKidney Corp., Jefferies LLC, At-the-Market Offering, ATM, Equity Offering, Common Stock, Capital Raise, SEC Filing, Form 8-K, Dilution, Shelf Registration, S-3